View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 20, 2020

Bio-Techne, Kantaro Biosciences to deliver Covid-19 antibody test kits

Bio-Techne has partnered with Kantaro Biosciences, a joint venture of Mount Sinai Health System with Renalytix AI, to deliver Covid-19 antibody test kits.

Bio-Techne has partnered with Kantaro Biosciences , a joint venture of Mount Sinai Health System with Renalytix AI, to deliver Covid-19 antibody test kits.

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

The partners will develop, manufacture, sell and distribute testing kits based on the Mount Sinai-developed Covid-19 serology test.

With the step, Bio-Techne and Kantaro Biosciences aim to enable the laboratories to conduct more than ten million tests in July and further increase the capabilities in the subsequent months.

The Kantaro’s IgG antibody test kit is an enzyme-linked immunosorbent assay designed to identify the presence of anti-Covid-19 antibodies. It also measures the titer (level) of antibodies that a person has produced.

The test kit uses two virus antigens, the full-length spike protein and its receptor-binding domain, necessary for viral entry into cells.

Bio-Techne and Kantaro Biosciences have also formed a joint commercialisation and distribution team to enable rapid distribution of the assay.

Bio-Techne president and CEO Chuck Kummeth said: “We are extremely excited to partner with Kantaro and Mount Sinai to launch what we believe will be a gold standard serology test for Covid-19.

“The Bio-Techne , Mount Sinai and Kantaro teams are working around the clock to develop this test and we are on track to achieve in approximately eight weeks what would typically take 18 months or more.

“As the world leader in ELISA assays, Bio-Techne has substantial capacity and the ability to scale production levels to support much of our nation’s needs. We look forward to providing the world with critical information related to past exposure to the virus.”

Related Companies

Free Report
img

Build resilience in the face of COVID-19 disruption

COVID-19 has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities. Are you interested in actionable insights on the business challenges induced by the pandemic? GlobalData's cross-sector report analyzes the significance of this major disruptive theme across industry verticals. It provides side-by-side research of alternative datasets to present you with unique quantitative analysis of the effects of COVID-19 and how these differ across sectors. Additionally, it offers qualitative analysis of each sector and analyzes COVID-19’s impact on leading companies. Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network